Karolinska Development

Karolinska Development Dividend

Dividend of Karolinska Development (KDV.ST) as of Nov 22, 2026.

Dividend

-SEK

Last updated:

How much dividend does Karolinska Development 2026 pay?

According to the latest status from November 2026, Karolinska Development paid a total of - SEK per share in dividends within the last 12 months. With the current Karolinska Development price of 0.00 SEK, this corresponds to a dividend yield of - %. A dividend is paid times per year.

Historical Karolinska Development Dividends

Historical Karolinska Development Dividends
PaydateDividend

Is the Karolinska Development Dividend Safe?

Karolinska Development has been increasing the dividend for 0 years.

Analysts expect a Dividend Cut of -100.00% for the current fiscal year.

Dividend Details

Understanding Karolinska Development's Dividend Distributions

Karolinska Development’s dividends are a portion of the company’s profits distributed to shareholders. It is a critical indicator of the company’s financial health and attractiveness to investors. Dividends provide investors with a steady income stream, in addition to any profits that may come from selling the stock at a higher price than the purchase price.

Year-to-Year Comparison

Examining Karolinska Development's dividend distributions over the years can highlight the company’s profitability and stability. A consistent or increasing dividend payout can indicate a financially healthy company with predictable earnings, while fluctuations or reductions in dividends can suggest underlying financial or operational challenges.

Impact on Investments

Karolinska Development's dividend payments are an essential factor for income-focused investors. A robust dividend payout can enhance the stock’s appeal, offering regular income in addition to potential capital gains. It also can indicate the company's confidence in its future earnings, making it a significant consideration in investment decisions.

Interpreting Dividend Fluctuations

Changes in Karolinska Development’s dividends can result from shifts in the company’s earnings, financial policies, or reinvestment strategies. An increase in dividends often signals financial stability, while a decrease may indicate a need to conserve cash or reinvest profits to fuel growth, each scenario having different implications for investors.

Karolinska Development Stock analysis

What does Karolinska Development do? Karolinska Development AB is a Swedish investment company focused on promoting innovative biotech companies and start-ups. The company was founded in 2003 by the government of the Stockholm region and Karolinska Institutet University. The business model of Karolinska Development is designed to make profitable investments in promising biotech companies. It specifically supports companies in the areas of cancer treatment, immunotherapy, cardiovascular diseases, as well as neurology and psychiatry. The company provides capital and expertise to turn promising innovations into successful products. Karolinska Development operates different divisions to fulfill this purpose, including Karolinska Development AB (parent company), Karolinska Development Life Science Venture AB (a specialized investment company), and Karolinska Development Management AB (portfolio management team). Karolinska Development has built a strong portfolio of companies developing innovative products and therapies. One example is Modus Therapeutics AB, which has developed a new therapy for the treatment of sickle cell anemia. Another example is Aprea AB, a developer of gene therapies for combating cancer using tumor cells and genetic sequencing. The company's history is marked by many successful investments and acquisitions. One example is the acquisition of BioChromix AB in 2012, which developed a new technology for rapid and precise diagnosis of infectious diseases. Karolinska Development also actively participates in supporting new start-ups and company formations to promote promising innovations. Karolinska Development AB plays an important role in the biotech industry and significantly supports research in drug development. Through its unique position as an investor and partner for innovative companies, Karolinska Development is a driving force in the field of biotechnology. The company's business field is characterized by high risk and requires strategic thinking and skillful maneuvering in the market. However, Karolinska Development has managed to build a solid foundation and establish itself as an important player in the biotech industry through targeted investments, acquisitions, and partnerships. In summary, Karolinska Development plays a vital role in the biotech industry in Sweden and worldwide. The company has produced many innovative companies and products through targeted investments and acquisitions, contributing to changing lives and combating diseases. With its unique position as an investor and partner for biotech companies, Karolinska Development is well-equipped to continue promoting new innovations and advancing drug development in the future. Karolinska Development is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Karolinska Development stock

Karolinska Development is assigned to the 'Health' sector.

The dividends of Karolinska Development are distributed in SEK.

Dividend calendar 2026

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

All Key Metrics — Karolinska Development